GenLab Biosolutions Private Limited, Bangalore, Karnataka, India.
Clin Lymphoma Myeloma Leuk. 2022 Jun;22(6):e392-e404. doi: 10.1016/j.clml.2021.12.003. Epub 2021 Dec 10.
Multiple Myeloma (MM) is one of the incurable types of cancer in plasma cells. While immense progress has been made in the treatment of this malignancy, a large percentage of patients were unable to adapt to such therapy. Additionally, these therapies might be associated with significant diseases and are not always tolerated well in all patients. Since cancer in plasma cells has no cure, patients develop resistance to treatments, resulting in R/R MM (Refractory/Relapsed Multiple Myeloma). BCMA (B cell maturation antigen) is primarily produced on mature B cells. It's up-regulation and activation are associated with multiple myeloma in both murine and human models, indicating that this might be an effective therapeutic target for this type of malignancy. Additionally, BCMA's predictive value, association with effective clinical trials, and capacity to be utilized in previously difficult to observe patient populations, imply that it might be used as a biomarker for multiple myeloma. Numerous kinds of BCMA-targeting medicines have demonstrated antimyeloma efficacy in individuals with refractory/relapsed MM, including CAR T-cell (Chimeric antigen receptor T cell) treatments, ADCs (Antibody-drug conjugate s), bispecific antibody constructs. Among these medications, CART cell-mediated BCMA therapy has shown significant outcomes in multiple myeloma clinical trials. This review article outlines CAR T cell mediated BCMA medicines have the efficiency to change the therapeutic pattern for multiple myeloma significantly.
多发性骨髓瘤（MM）是浆细胞不可治愈的癌症类型之一。尽管在这种恶性肿瘤的治疗方面取得了巨大进展，但仍有很大一部分患者无法适应这种治疗。此外，这些治疗方法可能与严重疾病相关，并非所有患者都能耐受。由于浆细胞癌症无法治愈，患者对治疗产生耐药性，导致 R/R MM（难治性/复发性多发性骨髓瘤）。BCMA（B 细胞成熟抗原）主要在成熟 B 细胞上产生。它的上调和激活与鼠类和人类模型中的多发性骨髓瘤有关，这表明它可能是这种恶性肿瘤的有效治疗靶点。此外，BCMA 的预测价值、与有效临床试验的关联，以及在以前难以观察到的患者群体中使用的能力，表明它可能被用作多发性骨髓瘤的生物标志物。许多种针对 BCMA 的药物在难治性/复发性 MM 患者中显示出抗骨髓瘤疗效，包括 CAR T 细胞（嵌合抗原受体 T 细胞）治疗、ADC（抗体药物偶联物）、双特异性抗体构建物。在这些药物中，CAR T 细胞介导的 BCMA 疗法在多发性骨髓瘤临床试验中显示出显著的疗效。本文综述了 CAR T 细胞介导的 BCMA 药物具有显著改变多发性骨髓瘤治疗模式的潜力。
